Humacyte
HUMA
168 hedge funds and large institutions have $104M invested in Humacyte in 2025 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 56 increasing their positions, 38 reducing their positions, and 31 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 38
23% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 31
6.86% more ownership
Funds ownership: 32.72% → 39.58% (+6.9%)
4% more funds holding
Funds holding: 162 → 168 (+6)
15% less call options, than puts
Call options by funds: $2.56M | Put options by funds: $3M
51% less capital invested
Capital invested by funds: $213M → $104M (-$109M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Heights Capital Management
San Francisco,
California
|
+$15.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$10.3M |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$8M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$7.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BHCM
Brevan Howard Capital Management
St. Helier,
Jersey
|
-$2.66M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.52M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$2.1M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$1.72M |
| 5 |
Jane Street
New York
|
-$1.31M |
HUMA Hedge Fund Activity: Q1 2025 in Review
168 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q1 2025, worth a combined $104M — down 51% from $213M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new HUMA positions and 31 closed out — a net gain of 7 holders — while 56 added to existing stakes and 38 trimmed.
The largest buyer was Heights Capital Management, opening a new position worth an estimated $15.1M. The largest seller was Brevan Howard Capital Management, cutting an estimated $2.66M.
- 168 institutional investors held Humacyte (HUMA) as of Q1 2025, up from 162 in Q4 2024.
- Funds reported $104M of Humacyte stock for Q1 2025, down 51% quarter-over-quarter.
- 38 funds opened new Humacyte positions in Q1 2025 and 31 closed out, a net change of +7 holders.
- The largest Humacyte buyer in Q1 2025 was Heights Capital Management, an estimated $15.1M added.
- The largest Humacyte seller in Q1 2025 was Brevan Howard Capital Management, an estimated $2.66M sold.
Based on aggregated 13F filings for Q1 2025.